Bayer is gambling $700 million on the ultimate success of its new hemophilia drugs now in Phase III testing. That's about how much Bayer's growing healthcare division plans to spend as it boosts its manufacturing capacity at two sites in Germany.
The careful, buttoned-down style favored by Novartis' top execs in Basel has been getting a makeover--at least on the architectural front.
A European Medicines Agency committee has recommended approval for another COPD treatment from GlaxoSmithKline, setting the stage for a likely nod in the coming months as the drugmaker looks to bolster its respiratory franchise.
Shares of PTC Therapeutics took a hit this morning, dropping about 20% after the European Medicines Agency threw its considerable weight against the biotech's application to gain a conditional approval for its Duchenne muscular dystrophy drug ataluren.
GlaxoSmithKline is inching toward European approval for albiglutide, winning a recommendation for its latest diabetes contender as the market for similar drugs gets more and more crowded.
European regulators handed Novartis a major setback in its quest to gain an approval for serelaxin, one of the pharma giant's top blockbuster prospects which earned "breakthrough" status at the FDA.
Ireland-based biopharma companies are all the rage these days. Blessed by advantageous tax laws, Elan and Warner Chilcott fell to takeover bids. And now that Jazz Pharmaceuticals has been bolstered by the addition of Gentium's rare-disease drug portfolio, it's back on the hit list of most likely takeover targets.
Belgium's TiGenix has hauled in about $13.7 million in debt financing, piling up cash as it works through Phase III with a stem cell treatment.
Ariad Pharmaceuticals seemed to dodge a bullet last month when the European Medicines Agency chose not to follow its U.S. counterpart, letting the troubled Iclusig stay on the market. Now, the regulator is reopening the books on Ariad's cancer drug, reviving concerns about the company's sole product and sending its shares down about 10%.
France's AB Science watched its shares tank as much as 31% on Friday after a European Medicines Agency panel rejected its gastrointestinal cancer treatment, casting serious doubts on the drug's potential approval.